Silo Pharma files PCT patent for Alzheimer's treatment using prucalopride and ketamine

Silo Pharma, Inc.

PCT patent application filed on August 25, 2023, for methods treating Alzheimer's disease.
Treatment combines prucalopride (5-HT4 agonist) with ketamine (NMDA antagonist).
Application seeks international patent protection; no granted status or trial data reported.

item 8.01 item 9.01

Silo Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-072602

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.